Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sylvain Ladoire

Showing results (111-120 of 167) with videos related to

Pageof 17
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 30, 2020
Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access ProgramLaurence Albiges, Aude Fléchon, Christine Chevreau, et al.
Immunity|March 13, 2012
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expressionFanny Chalmin, Grégoire Mignot, Mélanie Bruchard, et al.
Oncoimmunology|September 22, 2017
Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancerCourèche-Guillaume Kaderbhai, Corentin Richard, Jean David Fumet, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective studyManon de Vries-Brilland, Marine Gross-Goupil, Valérie Seegers, et al.
Autophagy|October 29, 2015
Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancerSylvain Ladoire, Frédérique Penault-Llorca, Laura Senovilla, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2026
Chemo-prAIdict Breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapyNatalia Fernanda Valderrama, Louis-Oscar Morel, Daniel Tshokola Mweze, et al.
European Urology|June 9, 2021
Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN TrialJean Courcier, Cécile Dalban, Brigitte Laguerre, et al.
European Urology|May 22, 2022
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed TomographyYohann Loriot, Matthieu Texier, Stéphane Culine, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2022
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinomaLucie Meynard, Derek Dinart, Blandine Delaunay, et al.
Breast Cancer (Tokyo, Japan)|August 10, 2023
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapySilvia Mihaela Ilie, Nathalie Briot, Guillaume Constantin, et al.
Pageof 17

Showing results (111-120 of 167) with videos related to

Sort By:
Pageof 17
European Journal of Cancer (Oxford, England : 1990)|November 30, 2020
Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access ProgramLaurence Albiges, Aude Fléchon, Christine Chevreau, et al.
Immunity|March 13, 2012
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expressionFanny Chalmin, Grégoire Mignot, Mélanie Bruchard, et al.
Oncoimmunology|September 22, 2017
Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancerCourèche-Guillaume Kaderbhai, Corentin Richard, Jean David Fumet, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective studyManon de Vries-Brilland, Marine Gross-Goupil, Valérie Seegers, et al.
Autophagy|October 29, 2015
Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancerSylvain Ladoire, Frédérique Penault-Llorca, Laura Senovilla, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2026
Chemo-prAIdict Breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapyNatalia Fernanda Valderrama, Louis-Oscar Morel, Daniel Tshokola Mweze, et al.
European Urology|June 9, 2021
Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN TrialJean Courcier, Cécile Dalban, Brigitte Laguerre, et al.
European Urology|May 22, 2022
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed TomographyYohann Loriot, Matthieu Texier, Stéphane Culine, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2022
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinomaLucie Meynard, Derek Dinart, Blandine Delaunay, et al.
Breast Cancer (Tokyo, Japan)|August 10, 2023
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapySilvia Mihaela Ilie, Nathalie Briot, Guillaume Constantin, et al.
Pageof 17